Promising combo aims to stop leukemia from coming back
NCT ID NCT04062266
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This study tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) from returning in patients who are already in remission. About 50 adults whose leukemia is in first remission and who are not ready for a stem cell transplant will receive this maintenance therapy. The goal is to see if the treatment extends the time before the cancer comes back, while monitoring for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.